Bimatoprost: Uses, Dosage, Side Effects and More

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Ophthalmic
Chronic open-angle glaucoma, Ocular hypertension

Adult: As 0.01% or 0.03% ophthalmic solution: Monotherapy or adjunctive therapy to β-blockers: Instil 1 drop in the affected eye(s) once daily in the evening.

Ophthalmic
Hypotrichosis of eyelashes

Adult: Latisse Place 1 drop on a sterile applicator and apply evenly along the skin of the upper eyelid margin at the base of eyelashes once daily at bedtime. Repeat the procedure for the opposite eyelid using a new applicator.

What are the brands available for Bimatoprost in Malaysia?

Lumigan

Special Precautions

Patient with known risk factors for macular oedema (e.g. aphakia, pseudophakia with torn posterior lens capsule); history of significant ocular viral infections (e.g. herpes simplex) or uveitis/iritis; COPD, asthma or compromised respiratory function due to other conditions; predisposition to low heart rate or low blood pressure. Renal and moderate to severe hepatic impairment. Pregnancy and lactation.

Adverse Reactions

Significant: Changed or increased brown pigmentation of the iris, eyelid skin, eyelashes and periorbital tissue; eyelash changes (including increased length, thickness, and number of lashes); macular oedema (including cystoid macular oedema); bacterial keratitis (when using multiple-dose containers); intraocular inflammation or exacerbation of inflammation; new or worsening asthma, dyspnoea; bradycardia, hypotension. Rarely, reactivation of previous corneal infiltrates or ocular infections.
Eye disorders: Conjunctival hyperaemia, punctate keratitis, eyelid pruritus or erythema; eye irritation, pain, discharge, or pruritus; corneal erosion, ocular burning, allergic conjunctivitis, blepharitis, asthenopia, worsening of visual acuity, conjunctival oedema, foreign body sensation, ocular dryness, photophobia, tearing, visual disturbances.
General disorders and administration site conditions: Instillation site irritation.
Investigations: Abnormal LFTs.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Hypertrichosis.
Vascular disorders: Hypertension.

Patient Counseling Information

Remove contact lenses before instillation and wait for at least 15 minutes before reinsertion.

Monitoring Parameters

Monitor IOP. Assess for ocular pigmentation changes.

Drug Interactions

May reduce IOP-lowering effect when used concomitantly with other prostaglandin analogues.

Action

Description:
Mechanism of Action: Bimatoprost, a synthetic prostamide analogue, reduces intraocular pressure (IOP) by increasing the aqueous humour outflow through the trabecular meshwork and uveoscleral routes. Its effect on eyelash growth is believed to occur by increasing the percentage and duration of hairs in the growth phase.
Onset: IOP reduction: Approx 4 hours.
Pharmacokinetics:
Absorption: Absorbed in small amounts. Time to peak plasma concentration: Within 10 minutes.
Distribution: Moderately distributed into body tissues. Volume of distribution: 0.67 L/kg. Plasma protein binding: Approx 88%.
Metabolism: Metabolised via oxidation, N-deethylation and glucuronidation to form various metabolites.
Excretion: Mainly via urine (≤67%); faeces (approx 25%). Elimination half-life: Approx 45 minutes.

Chemical Structure

Storage

Store between 2-25°C. Storage recommendations may vary among countries and between individual products. Refer to specific product guidelines.

MIMS Class

Antiglaucoma Preparations / Other Eye Preparations

ATC Classification

S01EE03 - bimatoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma and hypotrichosis of the eyelashes.

References

AFT Pharmaceuticals Ltd. Vizo-PF Bimatoprost 300 microgram/mL Eye Drop Solution data sheet 23 August 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 31/07/2025.

Bimatoprost 0.03% Solution/Drops (Somerset Therapeutics, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 31/07/2025.

Bimatoprost Sandoz 0.1 mg/mL Eye Drops, Solution (Sandoz Limited). MHRA. https://products.mhra.gov.uk. Accessed 31/07/2025.

Bimatoprost. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 31/07/2025.

Brayfield A, Cadart C (eds). Bimatoprost. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/07/2025.

Eyreida 0.3 mg/mL Eye Drops, Solution (Aspire Pharma Ltd). MHRA. https://products.mhra.gov.uk. Accessed 31/07/2025.

Joint Formulary Committee. Bimatoprost. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/07/2025.

Latisse 0.03% Solution/Drops (Allergan, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 31/07/2025.

Lumigan 0.01% Ophthalmic Solution (AbbVie Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 31/07/2025.

Lumigan 0.01% Solution/Drops (Allergan, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 31/07/2025.

Disclaimer: This information is independently developed by MIMS based on Bimatoprost from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com